

In the Claims

- 1-41. (Cancelled)
42. (Currently amended) An immunogenic composition comprising an isolated porcine circovirus type II (PCV2) and an additional porcine pathogen, wherein the PCV2 is inactivated or attenuated.
43. (Previously presented) The immunogenic composition of claim 42, wherein the isolated PCV2 is deposited at the ECACC and is selected from the group consisting of PCV2 Accession No. V97100219, PCV2 Accession No. V97100218, PCV2 Accession No. V97100217, PCV2 Accession No. V98011608, and PCV2 Accession No. V98011609.
44. (Previously presented) The immunogenic composition of claim 43, wherein the isolated PCV2 deposited at the ECACC is PCV2 Accession No. V97100219.
45. (Previously presented) The immunogenic composition of claim 43, wherein the isolated PCV2 deposited at the ECACC is PCV2 Accession No. V97100218.
46. (Previously presented) The immunogenic composition of claim 43, wherein the isolated PCV2 deposited at the ECACC is PCV2 Accession No. V97100217.
47. (Previously presented) The immunogenic composition of claim 43, wherein the isolated PCV2 deposited at the ECACC is PCV2 Accession No. V98011608.
48. (Previously presented) The immunogenic composition of claim 43, wherein the isolated PCV2 deposited at the ECACC is PCV2 Accession No. V98011609.
49. (Cancelled)
50. (Cancelled)
51. (Previously presented) The immunogenic composition of claim 42, wherein the PCV2 is propagated in porcine cells.
52. (Previously presented) The immunogenic composition of claim 42, wherein the PCV2 is propagated in a cell line.
53. (Previously presented) The immunogenic composition of claim 42, wherein the PCV2 is propagated in PK/15 cells.
54. (Currently amended) The immunogenic composition of ~~claim 50~~ claim 42, comprising about 10^3 to 10^6 TCID₅₀ of attenuated PCV2.
55. (Currently amended) The immunogenic composition of ~~claim 50, which~~ claim 42, wherein the PCV2 is attenuated and wherein the composition is in a freeze-dried form.

56. (Currently amended) The immunogenic composition of ~~claim 50~~ claim 55, further comprising a freeze-drying stabilizer.

57. (Previously presented) The immunogenic composition of claim 56, wherein the freeze-drying stabilizer is selected from the group consisting of SPGA, sorbitol, mannitol, starch, sucrose, dextran, glucose, albumin, casein and alkali metal phosphate.

58. (Currently amended) The immunogenic composition of ~~claim 50~~ claim 42, further comprising an adjuvant.

59. (Previously presented) The immunogenic composition of claim 58, wherein the adjuvant is selected from the group consisting of aluminium hydroxide, saponin, avridine (N,N-diocetadecyl-N',N'-bis(2-hydroxyethyl)-propanediamine), and DDA.

60. (Currently amended) The immunogenic composition of ~~claim 50~~ claim 42, wherein the composition is in the form of an emulsion.

61. (Previously presented) The immunogenic composition of claim 60, wherein the emulsion is a water-in-oil emulsion.

62. (Previously presented) The immunogenic composition of claim 60, wherein the emulsion is an oil-in-water emulsion.

63. (Currently amended) The immunogenic composition of ~~claim 49~~ claim 42, comprising about 10^6 - 10^8 TCID₅₀ of inactivated PCV2.

64. (Currently amended) The immunogenic composition of ~~claim 49~~ claim 42, comprising a concentrated culture of inactivated PCV2.

65-69. (Cancelled)

70. (Currently amended) The immunogenic composition of ~~claim 49~~ claim 42, wherein the PCV2 has been inactivated by a chemical agent.

71. (Previously presented) The immunogenic composition of claim 70, wherein the chemical agent is selected from the group consisting of formaldehyde, paraformaldehyde, beta-propiolactone and ethyleneimine.

72. (Previously presented) The immunogenic composition of claim 71, wherein the chemical agent is ethyleneimine.

73. (Previously presented) The immunogenic composition of claim 71, wherein the chemical agent is beta-propiolactone.

74. (Currently amended) The immunogenic composition of any one of ~~claims 42-50~~ claims 42-48, wherein the additional porcine pathogen is selected from the group consisting of Porcine Reproductive and Respiratory Syndrome (PRRS) virus, *Mycoplasma hyopneumonia*, *Actinobacillus pleuropneumoniae*, *Escherichia coli*, *Pasteurella multocida* (~~causing Atrophic Rhinitis~~), Pseudorabies virus (~~causing Aujeszky's disease~~), Swine Fever virus (~~causing Hog Cholera~~) and Swine Influenza virus.

75. (Previously presented) The immunogenic composition of claim 74, wherein the additional porcine pathogen is PRRS virus.

76. (Previously presented) The immunogenic composition of claim 74, wherein the additional porcine pathogen is *Mycoplasma hyopneumonia*.